At a glance
ClinicalIndex Comparison RecordPhase 1Active· 24 target
Drug / intervention
Recombinant human IL-21-expressing oncolytic vaccinia virus injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05914376Phase 1ActiveUpdate OverdueUpdated 4mo ago · Completion was 11mo agoEnrollment Stalled
A Phase I Dose Escalation Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Biological Properties of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Recombinant human IL-21-expressing oncolytic vaccinia virus injection for Advanced Solid Tumors. Active but no longer recruiting, targeting 24 participants across 2 sites.
Signals
Enrollment appears stalled
Detailed Summary
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1Active
2024202520262027
First PostedJun 2023
Enrollment StartJul 2023
Primary CompletionJul 2025
TodayJul 2026
Study CompletionJun 2027
First PostedJun 22, 2023
Enrollment StartJul 5, 2023
Primary CompletionJul 2, 2025
Study CompletionJun 10, 2027
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 3.0 years ago
Interventions
Recombinant human IL-21-expressing oncolytic vaccinia virus injectionbiological
hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.